It should be remarked that ibrutinib (the first-in class BTK inhibitor) and venetoclax itself, which are currently used in the treatment of CLL, have been shown to trigger ROS production by mechanisms that have not yet been fully elucidated. Here, BTK is linked to B-cell chronic lymphocytic leukemia.